Capsulated cellular nanosponges for the treatment of experimental inflammatory bowel disease

Summary

This preclinical study develops an oral macrophage-membrane nanosponge for inflammatory bowel disease, a condition sustained by epithelial damage, microbiome disruption, and a complex network of inflammatory signals. The investigators coated nanoparticles with macrophage membrane so they could act as decoy cells and bind multiple proinflammatory cytokines. To preserve the particles through the stomach and concentrate release in the colon, they placed them in gelatin capsules protected by an enteric polymer coating. The formulation was evaluated in mice with dextran-sulfate-sodium-induced colitis. Oral administration reduced disease severity when begun preventively and when treatment was delayed until after disease induction. Reported benefits included less intestinal inflammation and restoration of the epithelial barrier. The principal finding is that gastrointestinal protection and cell-membrane cytokine scavenging can be combined to deliver a multiplex anti-inflammatory material directly to the colon. This offers a local biomimetic alternative to treatments aimed at one cytokine or broad systemic immunosuppression. The abstract does not specify cytokine changes, microbiome effects, capsule release characteristics, comparison with approved therapies, chronic or repeated-dose safety, or whether the formulation can treat forms of IBD beyond the DSS mouse model.